# Tempus AI

> Tempus AI is a Chicago-based health technology company that has built one of the world's largest libraries of clinical and molecular data, paired with an AI operating system that helps physicians and researchers make data-driven decisions in oncology, cardiology, radiology, and beyond. Founded in 2015 by Groupon co-founder Eric Lefkofsky after his wife's cancer diagnosis, the company sequences patient genomes, structures messy clinical records, and turns that data into diagnostics and AI tools used across a majority of U.S. academic medical centers. It went public on Nasdaq in June 2024 under the ticker TEM.

- **Founded:** 2015
- **Headquarters:** Chicago, Illinois, United States
- **Founders:** Eric Lefkofsky (Founder & CEO)
- **Team size:** ~2,300-2,400 employees
- **Products:** Genomic Sequencing & Diagnostics, Tempus One, Tempus Hub, Tempus Lens, Tempus Next
- **Notable:** Built one of the world's largest libraries of clinical and molecular data (500+ petabytes; 45M+ de-identified patient journeys)., Completed a $410.7M Nasdaq IPO in June 2024 at a ~$6.1B valuation., Acquired Ambry Genetics for ~$692M (closed February 2025), expanding hereditary and germline testing.

## Products & services

- **Genomic Sequencing & Diagnostics** — Next-generation sequencing and molecular profiling tests across oncology, plus liquid biopsy and hereditary testing (bolstered by the Ambry Genetics acquisition).
- **Tempus One** — A generative-AI clinical assistant for oncology providers that uses LLMs to surface insights from unstructured patient data and simplify ordering and interpreting genomic tests.
- **Tempus Hub** — A platform for physicians to order diagnostic tests, review results, and interact with the clinical context around each patient.
- **Tempus Lens** — An agentic AI platform for exploring a vast database of millions of de-identified patient records to find patterns, identify targets, and inform clinical trial design for drug development.
- **Tempus Next** — An AI system for providers and researchers that analyzes patient data against care guidelines to flag patients who have deviated from the standard of care in near real time.
- **Data Licensing & Insights** — De-identified, multimodal real-world data and analytics licensed to pharma and biotech partners for research and drug development.

## Achievements

- Built one of the world's largest libraries of clinical and molecular data (500+ petabytes; 45M+ de-identified patient journeys).
- Completed a $410.7M Nasdaq IPO in June 2024 at a ~$6.1B valuation.
- Acquired Ambry Genetics for ~$692M (closed February 2025), expanding hereditary and germline testing.
- Grew revenue 75%+ year over year in early 2025.
- Launched generative-AI clinical assistant Tempus One and agentic AI platform Tempus Lens.

## Latest updates

- **2026-05** — Reported Q1 2026 revenue of $348.1M (up 36.1% YoY) and raised full-year 2026 guidance to ~$1.59-1.60B.
- **2026-05** — Unveiled the next generation of Tempus Lens, expanding its agentic AI platform for oncology drug development.
- **2025-02** — Completed the acquisition of Ambry Genetics for ~$692.3M.
- **2024-06** — Completed IPO on Nasdaq under ticker TEM, raising $410.7M; formed SB Tempus JV with SoftBank in Japan.

## Links

- Website: https://www.tempus.com
- LinkedIn: http://www.linkedin.com/company/tempusai
- Twitter/X: https://twitter.com/TempusAI
- YouTube: https://www.youtube.com/@TempusLabs
- Facebook: https://facebook.com/tempusai/

---

Profile page: https://yespress.io/tempus-ai
Published by YesPress — https://yespress.io
Last updated: 2026-06-01